• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Effexor XR (Venlafaxine Hydrochloride) Extended-release Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


July 2014

Summary View


Abnormal Bleeding
  • SSRIs and SNRIs, including Effexor XR, may increase the risk of bleeding events, ranging from  ecchymoses, hematomas, epistaxis, petechiae, and  gastrointestinal hemorrhage to life-threatening hemorrhage. Concomitant use… of or other drugs known to affect platelet function may add to this risk… 


August 2012

Summary View


Carcinogenesis, Mutagenesis, Impairment of Fertility
Impairment of Fertility
  • Reproduction and fertility studies of Venlafaxine in rats showed no adverse effects on male or female fertility at oral doses of up to 2 times the maximum recommended human dose of 225 mg/day on a mg/m2 basis.
  • However, reduced fertility was observed in a study in which male and female rats were treated with O-desmethylvenlafaxine (ODV), the major human metabolite of venlafaxine, prior to and during mating and gestation. This occurred at an ODV exposure (AUC) approximately 2 to 3 times that associated with a human venlafaxine dose of 225 mg/day.